IP Verse

Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof - EP3692983

The patent EP3692983 was granted to Celgene on Aug 11, 2021. The application was originally filed on May 14, 2009 under application number EP19213148A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3692983

CELGENE
Application Number
EP19213148A
Filing Date
May 14, 2009
Status
Opposition Rejected
Sep 6, 2025
Grant Date
Aug 11, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMay 11, 2022ELKINGTON AND FIFEADMISSIBLE
STADA ARZNEIMITTELMay 11, 2022KERNEBECKADMISSIBLE
HOFFMANN EITLEMay 10, 2022HOFFMANN EITLEADMISSIBLE
TEVA PHARMACEUTICALSMay 10, 2022D YOUNGADMISSIBLE
SANDOZMay 9, 2022TER MEER STEINMEISTER & PARTNERADMISSIBLE
LOTUS PHARMACEUTICALApr 29, 2022HAMM & WITTKOPPADMISSIBLE

Patent Citations (34) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20010990061-
DESCRIPTIONUS20050213823-
DESCRIPTIONUS20070698983-
DESCRIPTIONUS20070849958-
DESCRIPTIONUS20080029134-
DESCRIPTIONUS20080045823-
DESCRIPTIONWO2008US52124-
DESCRIPTIONUS2002051820
DESCRIPTIONUS2003039688
DESCRIPTIONUS2003104053
DESCRIPTIONUS2003104062
DESCRIPTIONUS2004162263
DESCRIPTIONUS2008057086
DESCRIPTIONUS4810643
DESCRIPTIONUS4999291
DESCRIPTIONUS5229496
DESCRIPTIONUS5391485
DESCRIPTIONUS5393870
DESCRIPTIONUS5528823
DESCRIPTIONUS5580755
DESCRIPTIONUS7038038
DESCRIPTIONUS7189740
DESCRIPTIONWO2008092127
DESCRIPTIONWO2009042767
OPPOSITIONEP2299984
OPPOSITIONUS2004186065
OPPOSITIONUS2006074046
OPPOSITIONWO2006034154
OPPOSITIONWO2008028193
OPPOSITIONWO2009013988
OPPOSITIONWO2009139888
OPPOSITIONWO2011014541
SEARCHUS2004186065
SEARCHWO2008028193

Non-Patent Literature (NPL) Citations (79) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- A.M. JUBB et al., J. Pathol., (20010000), vol. 195, pages 111 - 134-
DESCRIPTION- A.M. JUBB et al., J. Pathology, (20010000), vol. 195, pages 111 - 34-
DESCRIPTION- ANSELL, S.M. et al., Mayo Clin. Proc., (20050000), vol. 80, no. 8, pages 1087 - 97-
DESCRIPTION- APARICIO et al., Curr. Opin. Invest. Drugs, (20020000), vol. 3, no. 4, pages 627 - 33-
DESCRIPTION- BELINSKY, S.A., Nature Rev. Cancer, (20040000), vol. 4, pages 1 - 11-
DESCRIPTION- BENNETT J, M., Ann. Intern. Med., (19850000), vol. 103, no. 4, pages 620 - 5-
DESCRIPTION- BESA E. C., Med. Clin. North Am., (19920000), vol. 76, no. 3, pages 599 - 617-
DESCRIPTION- BROWN et al., Biochemical Preparations, (19550000), vol. 4, pages 70 - 76-
DESCRIPTION- CHEMICAL ABSTRACTS, Database accession no. 320-67-2-
DESCRIPTION- EMENS, L.A., Curr. Opinion Mol. Ther., (20010000), vol. 3, no. 1, pages 77 - 84-
DESCRIPTION- FOSTER et al., Adv. Drug Res., (19850000), vol. 14, pages 1 - 36-
DESCRIPTION- FROMMER, M. et al., Proc. Nat'I Acad. Set USA, (19920000), vol. 89, pages 1827 - 31-
DESCRIPTION- GATELY, J. Nucl. Med., (19860000), vol. 27, page 388-
DESCRIPTION- G. GARCIA-MANEROM. L. STOLTZM. R. WARDH. KANTARJIANS. SHARMA, Leukemia, (20080000), vol. 22, pages 1680 - 84-
DESCRIPTION- G. GIFFORD et al., Clin. Cancer Res., (20040000), vol. 10, pages 4420 - 26-
DESCRIPTION- GORDON, Drug Metab. Dispos., (19870000), vol. 15, page 589-
DESCRIPTION- GRUNDMANN et al., Chem. Ber., (19540000), vol. 87, pages 19 - 24-
DESCRIPTION- JEMAL et al., CA Cancer J Clin., (20050000), vol. 55, no. 1, pages 10 - 30-
DESCRIPTION- J,G. HERMANS.B. BAYLIN, N. Engl. J. Med., (20030000), vol. 349, pages 2042 - 54-
DESCRIPTION- J.G. HERMANS.B. - BAYLIN, N. Engl. J. Med, (20030000), vol. 349, pages 2042 - 54-
DESCRIPTION- K. APPLETON, J. Clin. Oncol., (20070000), vol. 25, no. 29, pages 4603 - 4609-
DESCRIPTION- KOMBLITH, J Clin. Oncol., (20020000), vol. 20, no. 10, pages 2441 - 2452-
DESCRIPTION- KUSHNER et al., Can. J. Physiol. Pharmacol., (19990000), vol. 77, pages 79 - 88-
DESCRIPTION- LAIRD, P.W., Nature Rev. Cancer, (20030000), vol. 3, pages 253 - 66-
DESCRIPTION- LI, Bioinformatics, (20020000), vol. 18, pages 1427 - 31-
DESCRIPTION- LIJINSKY, Food Cosmet. Toxicol., (19820000), vol. 20, page 393-
DESCRIPTION- LIJINSKY, J. Nat. Cancer Inst., (19820000), vol. 69, page 1127-
DESCRIPTION- LIST et al., J. Clin. Oncol., (19900000), vol. 8, page 1424-
DESCRIPTION- MANGOLD, Mutation Res., (19940000), vol. 308, page 33-
DESCRIPTION- M.V. BROCK et al., N. Engl. J Med, (20080000), vol. 358, no. 11, pages 1118 - 28-
DESCRIPTION- M.V. BROCK, N. Engl. J. Med, (20080000), vol. 358, no. 11, pages 1118 - 28-
DESCRIPTION- P.A. JONESS.B. BAYLIN, Nature Rev. Gen., (20020000), vol. 3, pages 415 - 28-
DESCRIPTION- PENICHET, M.L.MORRISON, S.L., J Immunol. Methods, (20010000), vol. 248, pages 91 - 101-
DESCRIPTION- P. FENAUX et al., Lancet Oneal., (20090000), vol. 10, no. 3, pages 223 - 32-
DESCRIPTION- PISKALA, Collect. Czech. Chem. Comm., (19670000), vol. 32, pages 3966 - 3976-
DESCRIPTION- PISKALA et al., Synthetic Procedures in Nucleic Acid Chemistry, Wiley Interscience, (19680000), vol. 1, pages 107 - 108-
DESCRIPTION- P.M. DAS et al., MoL Cancer, (20060000), vol. 5, no. 28-
DESCRIPTION- RAO, K.V., American Journal of Health-System Pharmacy, (20070000), vol. 64, no. 17, pages 1799 - 1807-
DESCRIPTION- SILVERMAN et al., Blood, (20050000), vol. 106, no. 11-
DESCRIPTION- SILVERMAN et al., J. Clin. Oneol., (20020000), vol. 20, no. 10, pages 2429 - 2440-
DESCRIPTION- S. NAND et al., Leukemia and Lymphoma, (20080000), vol. 49, no. 11, pages 2141 - 47-
DESCRIPTION- WADE, D., Chem. Biol. Interact., (19990000), vol. 117, page 191-
DESCRIPTION- ZELLO, Metabolism, (19940000), vol. 43, page 487-
DESCRIPTION- ZENT, C.S. et al., Current Oncology Reports, (20070000), vol. 9, pages 345 - 52-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VIDAZA safely and effectively. See full prescribing information for VIDAZA", Vidaza, (20080000), page 1, XP055735918-
OPPOSITION- Anonymous, "IARC monographs on the evaluation of carcinogenic risks to humans", Pharmaceutical Drugs, (19900000), vol. 50, pages 47 - 48, XP055735927-
OPPOSITION- Anonymous, "ICH Topic Q 6 A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products", Chemical Substances Glossary, (20000500), pages 1 - 4, XP055211303-
OPPOSITION- Anonymous, "Press Release: Pharmion's Oral Azacitidine Granted Fast Track Status for Myeodysplastic syndromes", FierceBiotech, (20070829), XP055640352-
OPPOSITION- Aulton's Pharmaceutics: The Design and Manufacture of Medicines, (20020000), pages 222 - 223, XP055924344-
OPPOSITION- "Dosage Form Design And Manufacture", Aulton M., Aulton's Pharmaceutics: The Design and Manufacture of Medicines Third Edition, Churchill Livingstone Elsevier, (20070000), pages 454 - 455, XP055926634-
OPPOSITION- Kenneth A Connors; Gordon L Amidon; Valentino J Stella, "055735934", Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists Second Edition, John Wiley & Sons, Inc., (19861100), page 239, XP055735934-
OPPOSITION- Leon Lachman; Herbert A Lieberman; Joseph L Kanig, "The Theory and Practice of Industrial Pharmacy Third Edition", The Theory and Practice of Industrial Pharmacy Third Edition, VARGHESE PUBLISHING HOUSE, (19860000), pages 331 - 332, XP055735916-
OPPOSITION- Michael E. Aulton, "dosage from design and manufacture ", Aulton's Pharmaceutics: The Design and Manufacture of Medicines, (20070101), pages 454 - 455, XP055924335-
OPPOSITION- Michael E. Aulton, "PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition", PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition, Elsevier, (20020000), pages 222 - 223, XP055735938-
OPPOSITION- National Cancer Institute; National Institutes Of Health, "Bioassay of 5-Azacytidine for Possible Carcinogenicity", Carcinogenesis, Technical Report Series No. 42, (19780000), pages 3 - 4, XP055352926-
OPPOSITION- Raymond C Rowe; Et Al, "Polymethacrylates", Handbook of Pharmaceutical Excipients Fifth Edition, Pharmaceutical Press, (20060000), pages 554 - 555, XP055498178-
OPPOSITION- SHARGEL et al., "Chapter 17: Modified-Release Drug Products", Applied Biopharmaceutics & Pharmacokinetics Fifth Edition, (20050000), page 515, XP055926624-
OPPOSITION- Yvonne Perrie, Thomas Rades, "chapter 1 controlling drug delivery ", Pharmaceutics - Drug Delivery and Targeting, (20100101), XP055924338-
OPPOSITION- NOTARI et al., "Kinetics and Mechanisms of Degradation of the Antileukemic Agent 5-Azacytidine in Aqueous Solutions", Journal of Pharmaceutical Sciences, (19750000), vol. 64, no. 7, doi:10.1002/jps.2600640704, pages 1148 - 1157, XP055735925
OPPOSITION- CHAN et al., "5-Azacytidine Hydrolysis Kinetics Measured by High-pressure Liquid Chromatography and 13C-NMR Spectroscopy", Journal of Pharmaceutical Sciences, (19790000), vol. 68, no. 7, doi:10.1002/jps.2600680705, pages 807 - 812, XP055735923
OPPOSITION- Kurkjian, C. ; Kummar, S. ; Murgo, A.J., "DNA Methylation: Its Role in Cancer Development and Therapy", CURRENT PROBLEMS IN CANCER, MOSBY, ST LOUIS, MO, US, US , (20080901), vol. 32, no. 5, doi:10.1016/j.currproblcancer.2008.08.002, ISSN 0147-0272, pages 187 - 235, XP025470418
OPPOSITION- Hirayama F., Uekama K., "Cyclodextrin-based controlled drug release system", Advanced Drug Delivery Reviews, Elsevier, Amsterdam , NL, Amsterdam , NL , (19990301), vol. 36, no. 1, doi:10.1016/S0169-409X(98)00058-1, ISSN 0169-409X, pages 125 - 141, XP002616323
OPPOSITION- GARCIA-MANERO et al., "A pilot pharmacokinetic study of oral azacitidine", Leukemia, (20080612), vol. 22, doi:10.1038/leu.2008.145, pages 1680 - 1684, XP037784418
OPPOSITION- Garcia-Manero G; Stoltz M L; Ward M R; Kantarjian H; Sharma S, "A pilot pharmacokinetic study of oral azacitidine", Leukemia, Nature Publishing Group UK, London, London, (20080612), vol. 22, no. 9, doi:10.1038/leu.2008.145, ISSN 0887-6924, pages 1680 - 1684, XP037784418
OPPOSITION- G Garcia-Manero, M L Stoltz, M R Ward, H Kantarjian, S Sharma, "A pilot pharmacokinetic study of oral azacitidine", Leukemia, Stockton Press, (20080901), vol. 22, no. 9, doi:10.1038/leu.2008.145, ISSN 08876924, pages 1680 - 1684, XP055217511
OPPOSITION- Amy Ziemba; Eugene Hayes; Burgess B Freeman; Tao Ye; Giuseppe Pizzorno, "Development of an Oral Form of Azacytidine: 2'3'5'Triacetyl-5-Azacytidine", Chemotherapy Research and Practice, vol. 2011, pages 1 - 9, XP055734492
OPPOSITION- STOLTZ et al., "Development of an Oral Dosage Form of Azacitidine: Overcoming Challenges in Chemistry, Formulation, and Bioavailability", Blood, (20060000), vol. 108, page 4850, XP002541912
OPPOSITION- Stoltz Maxine L; Etter Jeffirey B; Obradovic Tanja; Jia Richard, "Development of an oral dosage form of azacitidine: Overcoming challenges in chemistry, formulation, and bioavailability.", Blood, American Society of Hematology, US, US , (20060101), vol. 108, no. 11, ISSN 0006-4971, page 298B, XP009121611
OPPOSITION- Garcia-Manero Guillermo; Gore Steven D; Kambhampati Suman; Scott Bart L; Tefferi Ayalew; Cogle Christopher R; Edenfield William; Hetzer Joel; Kumar Keshava; Skikne Barry S, "Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes", Blood - Abstract 424, (20120000), vol. 120, no. 21, pages 1 - 4, XP086659772
OPPOSITION- M. R. Ward, M. L. Stoltz, J. B. Etter, L. M. Patton, G. Garcia Manero and S. Sharma, "An oral dosage formulation of azacitidine: A pilot pharmacokinetic study", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20070620), vol. 25, no. 18S, ISSN 0732-183X, page 7084, XP009121612
OPPOSITION- WARD et al., "An oral dosage formulation of azacitidine: A pilot pharmacokinetic study", Journal of Clinical Oncology, (20070600), vol. 25, no. 18, page 7084, XP009121612
OPPOSITION- GARCIA-MANERO et al., "Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes,Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia", J. Clin. Oncol., (20110620), vol. 29, no. 18, doi:10.1200/JCO.2010.34.4226, pages 2521 - 2527, XP055637078
OPPOSITION- Vaishali A Kilor; Nidhi P Sapkal; Jasmine G Awari; And Bharti D Shewale, "Development and Characterization of Enteric-Coated Immediate-Release Pellets of Aceclofenac by Extrusion/Spheronization Technique Using k-Carrageenan as a Pellitizing Agent", AAPS PharmSciTech, (20100300), vol. 11, no. 1, pages 336 - 343, XP055637096
OPPOSITION- COGLE et al., "Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia", The Oncologist, (20150000), vol. 20, doi:10.1634/theoncologist.2015-0165, pages 1 - 9, XP055637090
OPPOSITION- RAJ et al., "Azacytidine in the treatment of myelodysplastic syndromes", Therapeutics and Clinical Risk Management, (20060000), vol. 2, no. 4, doi:10.2147/tcrm.2006.2.4.377, pages 377 - 388, XP055640347
OPPOSITION- LEONE et al., "Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias", Curr Med Chem, (20080000), vol. 15, no. 13, pages 1274 - 87, XP055924347
OPPOSITION- Paul M Howell; Liu Zixing; Khong Hung T, "Demethylating Agents in the Treatment of Cancer", Pharmaceuticals, (20100000), vol. 3, no. 7, pages 2022 - 2044, XP055051867
SEARCH- STOLTZ, "Development of an Oral Dosage Form of Azacitidine: Overcoming Challenges in Chemistry, Formulation, and Bioavailability", ASH ANNUAL MEETING, (20060101), vol. 108, XP009121611 [Y] 1-15 * the whole document *
SEARCH- WARD, "An oral dosage formulation of azacitidine: A pilot pharmacokinetic study", JOURNAL OF CLINICAL ONCOLOGY, (20070701), vol. 25, no. 18S, XP009121612 [Y] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents